Paul G. Richardson, MD, on Multiple Myeloma: Results From the OPTIMISMM Trial

Posted: Wednesday, June 6, 2018

Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discusses phase III study findings on pomalidomide, bortezomib, and low-dose dexamethasone vs bortezomib and low-dose dexamethasone in lenalidomide-exposed patients with relapsed or refractory multiple myeloma.